Enhanc3D Genomics

Enhanced Genomics is a biotechnology therapeutics discovery and development company that uniquely defines causal biology from disease-associated variants on a genome-wide scale. Leveraging their proprietary 3D multi-omics platform and a data-rich human cell type-specific atlas, they can unlock decades of genetic data to accelerate drug discovery and precision medicine. Their platform translates massive amounts of disease-associated variant data into causal biology on a cell-type-specific basis, supporting target prioritization and identification, thereby more than doubling the probability of success for developing first-in-class therapeutics for common diseases with blockbuster potential. They also allow for patient stratification to improve clinical trials and have an active in-house target discovery and development program focused on common diseases with unmet needs, particularly autoimmune indications. Enhanced Genomics was spun out from the laboratories of Dr. Stefan Schoenfelder and Professor Peter Fraser, who pioneered research into the dynamic spatial organization of the genome at the Babraham Institute in Cambridge, UK.